Flow Chemistry Meets SPPS: Continuous Peptide Manufacturing Comes of Age

Solid-phase peptide synthesis (SPPS) has been the workhorse of peptide manufacturing since Merrifield’s Nobel-winning innovation in 1963. But the batch-based process has inherent limitations: each coupling cycle takes 30–90 minutes, resin swelling constrains scale-up, and the linear increase in waste with peptide length makes synthesis of peptides exceeding 30 residues economically challenging. Flow chemistry — where reagents are pumped through a heated column rather than mixed in a batch reactor — promises to rewrite these constraints.

Why Flow Now

Three developments have converged to make continuous-flow SPPS viable at production scale in 2026. First, the availability of thermostable resins that maintain swelling properties under elevated temperatures (60–90°C) enables coupling reactions to complete in 2–5 minutes rather than 30. Second, inline UV and IR monitoring provides real-time coupling efficiency data, allowing automated re-coupling of failed residues without human intervention. Third, the commercial availability of purpose-built flow peptide synthesizers — notably the CEM Liberty Blue 2.0 and Biotage Initiator+ Alstra — has lowered the barrier to entry for contract manufacturing organizations.

Efficiency Gains in Numbers

A 2025 head-to-head comparison published in Organic Process Research & Development compared batch vs. flow synthesis of a 36-residue GLP-1 analog:

• Total synthesis time: 11.2 hours (flow) vs. 38.5 hours (batch) — a 3.4× reduction
• Solvent consumption: 8.4 L/g peptide (flow) vs. 22.1 L/g (batch) — 62% less waste
• Crude purity: 72% (flow) vs. 58% (batch)
• Cost per gram (API): approximately ,200 (flow) vs. ,800 (batch)

For GLP-1 agonists — currently the highest-volume peptide drug class by revenue, with semaglutide alone generating over 1 billion in 2025 sales — these efficiency gains translate to tens of millions in annual manufacturing cost savings per product.

Remaining Barriers

Flow SPPS is not yet a drop-in replacement. The capital expenditure for a production-scale flow synthesizer exceeds 00,000, and experienced flow chemists are scarce. Method transfer from batch to flow requires re-optimization of every coupling and deprotection step. For peptides under 15 residues, batch SPPS remains more cost-effective due to lower setup complexity. Regulatory agencies have also been cautious: the FDA issued its first approval of a flow-manufactured peptide API (a 28-residue calcitonin analog) only in January 2026, setting a precedent but not yet establishing a clear regulatory pathway for all peptides.

The direction of travel, however, is clear. As GLP-1 demand strains global peptide manufacturing capacity, flow chemistry is moving from academic curiosity to industrial necessity. Companies that invest in flow infrastructure now will have a significant cost advantage when the next wave of multi-billion-dollar peptide drugs enters production.